InsiderTrades

Form 4 for ACRS Aclaris Therapeutics, Inc.

Accepted 2023-09-05 00:00:00 ET · period of report 2023-09-01 · accession 0001209191-23-048199 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-09-05 2023-09-01 ACRS Balthaser Kevin CFO F - Tax $7.90 -285 5,971 -5% -$2,252
D 2023-09-05 2023-09-01 ACRS Balthaser Kevin CFO M - OptEx — +1,000 6,256 +19% —
D 2023-09-05 2023-09-01 ACRS Balthaser Kevin CFO M - OptEx $0.00 -1,000 1,000 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-09-01 F D 285 $7.90 5,971 D — —
2 Common Common Stock 2023-09-01 M A 1,000 — 6,256 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
3 Derivative Restricted Stock Units 2023-09-01 M D 1,000 $0.00 1,000 D — · — to — 1,000 Common Stock (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F3) The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.